Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
OCUL Price Action
Last 7 days
-5.7%
Last 30 days
0.4%
Last 90 days
-9.8%
Trailing 12 Months
20.7%
OCUL RSI Chart
OCUL Valuation
OCUL Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
OCUL Fundamentals
OCUL Revenue
OCUL Earnings
OCUL Profitability
OCUL Investor Care
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 59.6M | 56.7M | 55.8M | 0 |
| 2024 | 59.8M | 61.1M | 61.4M | 63.7M |
| 2023 | 51.7M | 54.6M | 57.7M | 58.4M |
| 2022 | 49.4M | 49.9M | 49.7M | 51.5M |
| 2021 | 22.1M | 32.3M | 38.6M | 43.5M |
| 2020 | 6.3M | 7.3M | 12.3M | 17.4M |
| 2019 | 2.1M | 2.1M | 2.5M | 4.2M |
| 2018 | 1.8M | 2.0M | 2.0M | 2.0M |
| 2017 | 1.9M | 1.9M | 1.9M | 1.9M |
| 2016 | 1.8M | 1.8M | 1.8M | 1.9M |
| 2015 | 1.2M | 1.5M | 1.8M | 1.8M |
| 2014 | 200.5K | 391.0K | 581.5K | 772.0K |
| 2012 | 0 | 0 | 0 | 10.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| CEO | Mr. Antony Mattessich |
|---|---|
| WEBSITE | ocutx.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 274 |
